Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

(1) AMENDMENTS TO THE VALIDITY PERIOD OF THE RESOLUTIONS AND THE AUTHORISATION PERIOD IN RELATION TO THE PROPOSED ISSUANCE OF A SHARES; (2) PROPOSED CHANGE OF DOMESTIC AUDITOR FOR THE YEAR 2026; AND (3) PROPOSED PROVISION OF GUARANTEES FOR SUBSIDIARIES

This announcement is made by Shanghai INT Medical Instruments Co., Ltd.* (the "**Company**") pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Reference is made to the announcement of the Company dated 11 October 2026 (the "**Announcement**") in relation to, among other things, the proposed initial public offering of RMB ordinary shares (A Shares) and listing on the ChiNext Market of the Shenzhen Stock Exchange (the "**Proposed Issuance of A Shares**") and related matters. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that, at the fifteenth meeting of the fourth session of the Board held on 17 November 2026, the Board has considered and approved, among other things, the following resolutions:

I. AMENDMENTS TO THE VALIDITY PERIOD OF THE RESOLUTIONS AND THE AUTHORISATION PERIOD IN RELATION TO THE PROPOSED ISSUANCE OF A SHARES

As disclosed in the Announcement, the Board considered and approved on 10 October 2026 the resolution on the Company's application for the initial public offering and listing on the ChiNext Market (the "**Issuance Resolution**") and the resolution on the proposed authorisation by the general meeting to the Board to handle all matters in relation to the initial public offering and listing on the ChiNext Market (the "**Authorisation Resolution**"). Having considered the relevant regulatory requirements, the Board has considered and approved to amend the validity period of the Issuance Resolution and the authorisation period of the Authorisation Resolution as follows:

Item	Original	As amended
Validity period of the Issuance Resolution	24 months from the date of approval at the general meeting of the Company; if the Company obtains the registration approval document from the CSRC within the validity period, the validity period shall be automatically extended to the date of completion of the Proposed Issuance of A Shares.	12 months from the date of approval at the general meeting of the Company.
Authorisation period of the Authorisation Resolution	12 months from the date of approval at the general meeting; if the Proposed Issuance of A Shares obtains the CSRC's consent to registration within the authorisation period, the authorisation period shall be automatically extended to the date of completion of the Proposed Issuance of A Shares.	12 months from the date of approval at the general meeting.

Save for the above amendments, all other contents of the Issuance Resolution and the Authorisation Resolution remain unchanged.

II. PROPOSED CHANGE OF DOMESTIC AUDITOR FOR THE YEAR 2026

In order to coordinate and advance the Proposed Issuance of A Shares and enhance the efficiency of the domestic audit and avoid duplication of audit work, and as considered and approved by the audit committee of the Board (the "**Audit Committee**"), the Board proposes to terminate the engagement of KPMG Huazhen LLP ("**KPMG Huazhen**") as the domestic auditor of the Company for the year 2026, and proposes to appoint BDO China Shu Lun Pan Certified Public Accountants LLP ("**BDO**") as the domestic auditor of the Company for the year 2026, responsible for the audit of the financial statements prepared in accordance with the China Accounting Standards for Business Enterprises (the "**Proposed Change of Domestic Auditor**"). BDO has been engaged by the Company as the special audit institution for the Proposed Issuance of A Shares. As the financial statements of the Company for the year ending 31 December 2026 will form part of the reporting period of the financial information to be included in the application documents for the Proposed Issuance of A Shares, the Board considers that the appointment of BDO as the domestic auditor for the year 2026 will avoid duplication of audit work and enhance the efficiency of the domestic audit.

KPMG Huazhen has served as the domestic auditor of the Company since the year 2023, and was appointed as the domestic auditor of the Company for the year 2026 at the annual general meeting held on 28 May 2026. The Proposed Change of Domestic Auditor relates only to the domestic auditor of the Company. KPMG will continue to serve as the international auditor of the Company for the year 2026, responsible for the audit of the financial statements prepared in accordance with the Hong Kong Financial Reporting Standards, on which the annual results announcement and annual report of the Company published in accordance with the Listing Rules are based. Accordingly, the Proposed Change of Domestic Auditor will not affect the audit of such financial statements or the publication of the annual results and annual report of the Company for the year ending 31 December 2026.

The Proposed Change of Domestic Auditor is subject to the approval of the Shareholders at the forthcoming general meeting of the Company. The term of office of BDO will commence from the date of approval at the general meeting and end at the conclusion of the next annual general meeting of the Company. The audit fee of BDO for the audit of the domestic financial statements of the Company for the year 2026 is expected to be RMB500,000, which was determined with reference to the scope and complexity of the audit, the expected time and resources to be devoted, the audit timetable and the prevailing market rates. The key assumptions underlying such fee

include that (i) the business scale of the Group for the year 2026 will increase; (ii) the scope of consolidation of the Group for the year 2026 will increase; (iii) there will be no unplanned material acquisition, disposal or restructuring during the year; and (iv) there will be no unidentified material internal control deficiency or material misstatement. The audit fee of KPMG Huazhen for the domestic audit for the year 2025 was RMB400,000. The difference is mainly attributable to the expected increase in the overall business scale of the Group for 2026 and the increase in the scope of consolidation for the year 2026. The Board will also propose that the general meeting authorise the Board to approve reasonable adjustments to the audit fee of BDO which are proportionate to any change in the audit scope, and authorise the chairman of the Board to sign the relevant engagement agreement on behalf of the Company.

BDO is a PRC certified public accounting firm which has completed the filing for engaging in securities services business. The Audit Committee has assessed, among other things, the qualifications, professional competence, resources, independence and audit plan of BDO. BDO plans to carry out the audit planning and preliminary audit work and communicate with the Audit Committee in December 2026, conduct the year-end fieldwork from January to March 2027, and issue the audit report on the domestic financial statements by the end of April 2027. Having regard to the above and the fact that BDO has been conducting the audit work for the Proposed Issuance of A Shares, the Audit Committee considers that BDO is capable of completing the audit for the year 2026 in a timely manner while maintaining audit quality.

KPMG Huazhen has confirmed to the Board that there are no matters in relation to the Proposed Change of Domestic Auditor that need to be brought to the attention of the Shareholders. The Board and the Audit Committee also confirmed that, there is no disagreement between the Company and KPMG Huazhen, there are no unresolved audit issues and there are no other matters in relation to the Proposed Change of Domestic Auditor that need to be brought to the attention of the Shareholders.

The Board would like to express its sincere gratitude to KPMG Huazhen for its professional services rendered to the Company during its tenure of office.

III. PROPOSED PROVISION OF GUARANTEES FOR SUBSIDIARIES

In order to meet the funding needs of the daily operations and business development of the Company and its subsidiaries and to enhance their capital operation capability, the Board proposes that the Company provide guarantees for loans to be applied for from

banks and other financial institutions by six subsidiaries within the scope of its consolidated financial statements, in an aggregate amount of not more than RMB1,430 million (the "**Proposed Guarantees**"), details of which are set out below:

Guaranteed party	**Equity interest held by the Company**	**Guarantee amount** *(RMB million)*
Shandong INT Medical Instruments Co., Ltd.* (山東瑛泰醫療器械有限公司)	100%	700
Hangzhou INT Medical Technology Co., Ltd.* (杭州瑛泰醫療科技有限公司)	100%	400
Xiamen INT Medical Technology Co., Ltd.* (廈門瑛泰醫療科技有限公司)	100%	150
Shanghai INT Purun Medical Instruments Co., Ltd.* (上海瑛泰璞潤醫療器械有限公司)	62.9787%	100
Shanghai INT Biotechnology Co., Ltd.* (上海瑛泰生物科技有限公司)	100%	50
Shanghai Qimu Medical Instruments Co., Ltd.* (上海七木醫療器械有限公司)	90%	30
Total		**1,430**

As at the date of this announcement, the Company has not entered into any guarantee agreement or letter of intent in respect of the Proposed Guarantees. The Proposed Guarantees will be provided by way of joint and several liability guarantees, and the guarantee period will be subject to the guarantee agreements to be finally entered into between the Company and the relevant banks and other financial institutions. The Board will propose that the general meeting authorise the chairman of the Board to sign, on behalf of the Company, all legal documents in relation to such loans and guarantees within the above guarantee amount.

Pursuant to the relevant provisions of the articles of association of the Company, the Proposed Guarantees are subject to the approval of the Shareholders at the forthcoming general meeting of the Company.

Listing Rules implications

As each of the guaranteed parties is a subsidiary of the Company, the Proposed Guarantees do not constitute notifiable transactions of the Company under Chapter 14 of the Listing Rules pursuant to Rule 14.04(1)(e) of the Listing Rules. To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, no connected person of the Company at the issuer level is entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of Shanghai INT Purun Medical Instruments Co., Ltd.* or Shanghai Qimu Medical Instruments Co., Ltd.*, individually or together. Accordingly, neither of them is a connected subsidiary of the Company under Rule 14A.16 of the Listing Rules, and the Proposed Guarantees do not constitute connected transactions of the Company under Chapter 14A of the Listing Rules.

IV. GENERAL

A circular containing, among other things, details of the Proposed Change of Domestic Auditor and the Proposed Guarantees, together with a notice of the general meeting, will be despatched to the Shareholders in due course.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
17 November 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Ms. Chen Hongqin, Mr. Zhang Hong and Ms. Chen Jie (employee representative Director) as non-executive Directors, and Mr. Xu Congli, Dr. Zhang Peng and Dr. Lai Wan Lung as independent non-executive Directors.

* *For identification purposes only*